Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis

P M Furneri; G Rappazzo; M P Musumarra; P Di Pietro; L S Catania; L S Roccasalva

doi:10.1128/AAC.45.10.2958-2960.2001

Two new point mutations at A2062 associated with resistance to 16-membered macrolide antibiotics in mutant strains of Mycoplasma hominis

Antimicrob Agents Chemother. 2001 Oct;45(10):2958-60. doi: 10.1128/AAC.45.10.2958-2960.2001.

Authors

P M Furneri¹, G Rappazzo, M P Musumarra, P Di Pietro, L S Catania, L S Roccasalva

Affiliation

¹ Dipartimento di Scienze Microbiologiche e Scienze Ginecologiche, Università degli Studi, Via Androne 81, 95124 Catania, Italy. [email protected]

Abstract

We describe two mutants of Mycoplasma hominis PG-21 which show resistance to 16-membered macrolides but susceptibility to lincosamides, obtained by in vitro exposure to increasing doses of josamycin. The 23S rRNA gene showed that each had a mutation (A2062G and A2062T) corresponding to nucleotide 2062 in Escherichia coli, which was associated with the acquired phenotype.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology
Base Sequence
DNA, Bacterial / analysis
Drug Resistance, Bacterial / genetics*
Macrolides
Molecular Sequence Data
Mycoplasma hominis / drug effects
Mycoplasma hominis / genetics*
Phenotype
Point Mutation
RNA, Ribosomal, 23S / genetics*
Sequence Homology, Nucleic Acid

Substances

Anti-Bacterial Agents
DNA, Bacterial
Macrolides
RNA, Ribosomal, 23S

Associated data

GENBANK/AF184237
GENBANK/AF317663